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Exploring the Adverse Effects of CAR-T Therapy:
A Case Report of Potential MINOCA in CAR-T
Danielle Verghese, PGY-1, Adam Binder, MD, Colin Thomas, MD

INTRODUCTION
The discovery and application of Chimeric Antigen
Receptor T-Cell Therapy (CAR-T) has marked a new era
in cancer treatment. CAR-T is a novel therapy with a
relatively small treatment population, and we have yet
to identify the full spectrum of its adverse effects. 1
There are well-established approaches to the most
common adverse effects, principally cytokine release
syndrome (CRS), but there is limited literature discussing
the nature of cardiotoxicity in CAR-T, much less its
mechanism or management. 2, 3 This case study
discusses the development of myocardial infarction
with no obstructive coronary atherosclerosis (MINOCA)
in a patient treated with CAR-T.

CASE PRESENTATION
A 48-year-old man with a history of Stage IV Diffuse
Large B- Cell Lymphoma refractor y to R- CHOP
alternating with high-dose methotrexate and cytarabine,
craniospinal irradiation, and haploidentical stem cell
transplant, underwent CD 19-directed CAR-T. His
post-treatment course was complicated by marrow
aplasia and infection, but he ultimately responded to
therapy and achieved complete remission.
Five months after undergoing CAR-T, the patient
presented with persistent malaise and vague abdominal
pain. Initial assessment found him to be cachectic and
frail, and he was admitted for further investigation of
failure to thrive (FTT). An extensive workup of endocrine,
metabolic, and infectious causes of FTT was unrevealing.
Labs showed stable neutropenia (ANC 0.4) and anemia
(Hgb 9.7) with no evidence of adrenal insufficiency,
thyroid dysfunction, vitamin deficiencies, nor bacterial,
viral, or fungal infections. EGD did not reveal any
significant gastrointestinal pathology, only patches of
chronic, mild inflammation.
On the sixth day of hospitalization, the patient reported
left shoulder pain. Telemetry showed an acute increase
in heart rate, from a baseline sinus tachycardia of 100-110
bpm to 130-140 bpm. EKG revealed new inferior ST
segment elevations. Echocardiography identified newly
depressed ejection fraction (45%) and basal to
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mid-anterior and anteroseptal wall motion abnormalities,
where previous studies had shown normal EF and no
segmental wall motion abnormalities. High-sensitivity
troponins were elevated and continued to rise from –
344 ng/L followed by 366 ng/L in the setting of normal
renal function. Subsequent cardiac catheterization
revealed no obstructive coronary artery disease.
Altogether, the evidence for myocardial injury in the
absence of obstructive coronar y arter y disease
culminated in a diagnosis of MINOCA.
A multi-disciplinary team including Cardiology and
Hematology-Oncology reviewed possible etiologies of
cardiac injury. Although the patient had previously
received doxorubicin chemotherapy (total of 229 mg, 20
months prior to this admission), the acute onset of ST
elevations and dynamic troponins were atypical for
anthracycline-induced cardiomyopathy.4 Similarly, the
presentation was not typical for stress-induced cardiomyopathy, especially in the absence of an acute trigge.5
The constellation of cardiac findings was attributed to
myocarditis, but the underlying cause remained unclear.
The patient was not taking any medications commonly
associated with myocarditis. Infectious workup was
negative including blood cultures, urine cultures,
influenza A and B, respiratory pathogen panel, EBV, CMV,
tuberculosis and aspergillus testing. Of note, testing for
coxsackie A and B, HIV, and HSV was not performed.
Previous reports have posited a CRS-mediated
mechanism of cardiac injury in CAR-T, but CRS typically
peaks days after treatment, and would be uncommon
months after CAR-T infusion. 6 Another proposed
mechanism considers off-target cross-reactivity, leading
to an autoimmune myocarditis.6 The next best steps to
workup myocarditis would have been further infectious
testing, cardiac MRI, endomyocardial biopsy, but these
were deferred as the patient was high-risk for invasive
procedures and the findings were unlikely to change
clinical management.
Besides myocarditis, other etiologies of MINOCA include
coronar y vasospasm, coronar y microvascular
dysfunction, and thrombophilia7. These were not further
investigated during the patient’s hospitalization.
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